August 11, 2011 in Nation/World

Gene therapy shows promise against leukemia

Stephanie Nano Associated Press
 
The patients

The study involved three men with very advanced cases of chronic lymphocytic leukemia, or CLL. The accepted treatment now is bone marrow or stem cell transplants, which don’t always work and carry a high risk of death.

NEW YORK – Scientists are reporting the first clear success with a new approach for treating leukemia – turning the patients’ own blood cells into assassins that hunt and destroy their cancer cells.

They’ve only done it in three patients so far, but the results were striking: Two appear cancer-free up to a year after treatment, and the third patient is improved but still has some cancer. Scientists are already preparing to try the same gene therapy technique for other kinds of cancer.

“It worked great. We were surprised it worked as well as it did,” said Dr. Carl June, a gene therapy expert at the University of Pennsylvania. “We’re just a year out now. We need to find out how long these remissions last.”

He led the study, published Wednesday by two journals, New England Journal of Medicine and Science Translational Medicine.

Scientists have been working for years to find ways to boost the immune system’s ability to fight cancer. Earlier attempts at genetically modifying bloodstream soldiers called T-cells have had limited success; the modified cells didn’t reproduce well and quickly disappeared.

June and his colleagues made changes to the technique, using a novel carrier to deliver the new genes into the T-cells and a signaling mechanism telling the cells to kill and multiply.

That resulted in armies of “serial killer” cells that targeted cancer cells, destroyed them, and went on to kill new cancer as it emerged. It was known that T-cells attack viruses that way, but this is the first time it’s been done against cancer, June said.

For the experiment, blood was taken from each patient and T-cells removed. After they were altered in a lab, millions of the cells were returned to the patient in three infusions.

The researchers described the experience of one 64-year-old patient in detail.

There was no change for two weeks, but then he became ill with chills, nausea and fever. He and the other two patients were hit with a condition that occurs when a large number of cancer cells die at the same time – a sign that the gene therapy is working.

“It was like the worst flu of their life,” June said. “But after that, it’s over. They’re well.”

The main complication seems to be that this technique also destroys some other infection-fighting blood cells; so far the patients have been getting monthly treatments for that.

Penn researchers want to test the gene therapy technique in leukemia-related cancers, as well as pancreatic and ovarian cancer, he said.

Other institutions are looking at prostate and brain cancer.

Dr. Walter J. Urba, of the Providence Cancer Center in Portland, called the findings “pretty remarkable” but added a note of caution because of the size of the study.

“It’s still just three patients. Three’s better than one, but it’s not 100,” said Urba, one of the authors of an editorial on the research that appears in the New England Journal.

What happens long-term is key, he said: “What’s it like a year from now, two years from now, for these patients.”

But Dr. Kanti Rai, a blood cancer expert at New York’s Long Island Jewish Medical Center, could hardly contain his enthusiasm, saying he usually is more reserved in his comments on such reports.

“It’s an amazing, amazing kind of achievement,” said Rai, who had no role in the research.

© Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Get stories like this in a free daily email


Please keep it civil. Don't post comments that are obscene, defamatory, threatening, off-topic, an infringement of copyright or an invasion of privacy. Read our forum standards and community guidelines.

You must be logged in to post comments. Please log in here or click the comment box below for options.

comments powered by Disqus